Jakob Siedlecki

Munich, BY 80336, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 87 publications

Photodynamic Therapy in Central Serous Chorioretinopathy: Treatment Timing, Anatomical Response, and Recurrence in a Large Real-World Cohort.

Photodynamic Therapy in Central Serous Chorioretinopathy: Treatment Timing, Anatomical Response, and Recurrence in a Large Real-World Cohort.

Journal: Ophthalmology and therapy

Published: April 28, 2026

Efficacy of 2 mg vs. High-Dose 8 mg Aflibercept in Neovascular Age Related Macular Degeneration.

Efficacy of 2 mg vs. High-Dose 8 mg Aflibercept in Neovascular Age Related Macular Degeneration.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: December 15, 2025

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

Journal: Ophthalmic research

Published: December 04, 2025

Mechanisms of Gas-Induced Posterior Vitreous Detachment: A Look Behind the Bubble Using Optical Coherence Tomography in Prone Position.

Mechanisms of Gas-Induced Posterior Vitreous Detachment: A Look Behind the Bubble Using Optical Coherence Tomography in Prone Position.

Journal: Journal of clinical medicine

Published: September 26, 2025

Title Not Found

Title Not Found

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: September 18, 2025

INNER FOVEAL IRREGULARITIES AFTER VITREOMACULAR DETACHMENT: A Morphologic Risk Factor for Macular Hole Formation in the Fellow Eye.

INNER FOVEAL IRREGULARITIES AFTER VITREOMACULAR DETACHMENT: A Morphologic Risk Factor for Macular Hole Formation in the Fellow Eye.

Journal: Retina (Philadelphia, Pa.)

Published: September 16, 2025

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Journal: Life (Basel, Switzerland)

Published: September 16, 2025

Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome.

Pentraxin-3 and Lipocalin-2 are decreased in patients with uveal effusion syndrome.

Journal: International ophthalmology

Published: August 04, 2025

Age-related macular degeneration: Current treatment options and innovative research approaches

Age-related macular degeneration: Current treatment options and innovative research approaches

Journal: MMW Fortschritte der Medizin

Published: May 01, 2025

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema.

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema.

Journal: Ophthalmology and therapy

Published: March 16, 2025

Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.

Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.

Journal: International journal of retina and vitreous

Published: February 20, 2025

Suprachoroidal Delivery of Corticosteroid Slow-Release Implants for the Treatment of Cystoid Macular Edema.

Suprachoroidal Delivery of Corticosteroid Slow-Release Implants for the Treatment of Cystoid Macular Edema.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: February 17, 2025

Showing 1-12 of 87

Last Updated: 09/26/2026